Health Care

Trader Alert: Unusual Volume Spotted in Sage Therapeutics, Inc. (NASDAQ:SAGE)

Trader Alert: Unusual Volume Spotted in Sage Therapeutics, Inc. (NASDAQ:SAGE)”

Current levels places Sage Therapeutics, Inc. While the stock price moved along with the volume change, shares are touching $74.89. Palo Alto Investors LLC purchased a new stake in shares of Sage Therapeutics during the second quarter worth approximately $12,591,000. FMR LLC now owns 5,590,527 shares of the biopharmaceutical company's stock worth $397,319,000 after purchasing an additional 15,451 shares during the period.

Sage Therapeutics Inc said it would stop developing its drug to treat a life-threatening seizure disorder after the treatment failed to meet the main goal of a key study. The Middleton & Co Inc holds 60,830 shares with $5.25M value, up from 38,680 last quarter. Finally, Vanguard Group Inc. boosted its holdings in shares of Sage Therapeutics by 10.8% in the 1st quarter. During the same quarter previous year, the firm posted ($1.08) earnings per share. For the week, the stock is performing 1.75%. Finally, MARSHALL WACE ASIA Ltd bought a new position in shares of Sage Therapeutics in the first quarter valued at $35,493,000. Jpmorgan Chase & reported 998,787 shares or 0.01% of all its holdings.

Among 14 analysts covering SAGE Therapeutics (NASDAQ:SAGE), 11 have Buy rating, 0 Sell and 3 Hold. If you are viewing this article on another domain, it was illegally copied and republished in violation of worldwide copyright legislation. The legal version of this news story can be accessed at The stock of SAGE Therapeutics Inc (NASDAQ:SAGE) has "Outperform" rating given on Wednesday, June 29 by BMO Capital Markets. (SAGE) was up +1.75% during the last day of trading, with a day high of 89.83. The firm's 50 day moving average price is $50.54 and its 200-day moving average price is $45.86. The company has market cap of $5.29 billion. SAGE Therapeutics Inc (NASDAQ:SAGE) has risen 116.45% since September 12, 2016 and is uptrending. The biopharmaceutical company reported ($1.88) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($1.63) by $0.25. During the same period in the prior year, the company posted ($1.08) EPS.

"The SRSE study showed little signal and we'd be very surprised if Sage continued clinical development in this context", Leerink Research analyst Paul Matteis wrote in a client note. Cowen and Company restated a "buy" rating and set a $100.00 target price on shares of Sage Therapeutics in a report on Friday, August 4th. On Friday, July 14 the stock rating was maintained by Stifel Nicolaus with "Buy".

03/11/2016 - Lake Street began new coverage on Sage Therapeutics, Inc. giving the company a "buy" rating. They set a "buy" rating and a $104.00 target price for the company.

05/10/2017 - Sage Therapeutics, Inc. had its "buy" rating reiterated by analysts at Canaccord Genuity. Four analysts have rated the stock with a hold rating, eight have assigned a buy rating and two have issued a strong buy rating to the company. BMO Capital Markets reissued a "positive" rating and issued a $68.00 target price on shares of Sage Therapeutics in a research report on Monday.

The late-stage trial was testing Sage's drug, brexanolone, in patients with super-refractory status epilepticus (SRSE) whose seizures persisted despite earlier treatments. The Company's lead product candidate, SAGE-547 is an intravenous formulation of allopregnanolone, a neurosteroid that acts as a synaptic and extrasynaptic modulator of the Gamma-Amino Butyric Acid-A (GABAA) receptor.

Like this



12 September 2017
Israel to sue Amnesty International over BDS declaration
Israel disputes this, as there was no legal sovereign there prior to its taking control, and claims a historical tie to the biblical Judea and Samaria.

12 September 2017
Slack Learns a Few New Languages
About a year ago, the company had 4 million daily active users and had more than $100 million in annual recurring revenue. But it's still full of missives from people outside of our company who I work with for one reason or another.

12 September 2017
IT Smashes OZ Box Office Record For Horror Films
It also surpassed the entire domestic gross for fellow Warner Bris horror blockbuster The Conjuring 2 in just three days. Costing a very modest $35 million to produce, It has amassed nearly $200 million worldwide since Friday.

12 September 2017
Home Capital Shareholders Reject Buffett's Expanded Stake
Home Capital's executives have emphasized the importance of having an investor of Buffett's credibility backing the company. The rejection follows a recommendation by Institutional Shareholder Services that shareholders vote against the proposal.

12 September 2017
DowDuPont Tweaks Breakup Plan; Stock Set To Break Out To Buy
Strs Ohio owned approximately 0.08% of Dow Chemical worth $57,930,000 at the end of the most recent reporting period. Jefferies Group LLC reiterated a "buy" rating on shares of Dow Chemical in a research report on Tuesday, August 29th.

12 September 2017
Supreme Court Backs Broad Enforcement Of Travel Ban - For Now
Constitution and First Amendment by discriminating against Muslims, will be reviewed by the Supreme Court in October. The U.S. government can still "bar tens of thousands of refugees from entering the country", Hawaii's lawyers said.

12 September 2017
Woman accused of shooting homeless man who asked her to move Porsche
He believes she is being unfairly prosecuted and that authorities are intentionally ignoring any threat Melton may have posed. Jesse Quackenbush, Katie's father, has a different account of what happened. "She didn't know that she hit him".

12 September 2017
Jack Ma Dances To Michael Jackson's Songs On Alibaba's Birthday
In 2009, at the company's 10th anniversary, he donned a heavy metal wig and performed parts of "The Lion King" in front of thousands of employees.

12 September 2017
Oise: l'auteur du triple assassinat était un policier
La piste terroriste est écartée selon la préfecture de l'Oise , le Parquet tiendra une conférence de presse à 17h. Des gendarmes ont été appelés dimanche au domicile du couple en raison d'un différend familial.

12 September 2017
Liam Neeson says his days as an action hero are over
Taken would gross $226 million worldwide, launching a franchise and re-branding Neeson as an action star in the Bruce Willis mold. Ballymena actor Liam Neeson has said he won't be making anymore action movies - citing his age as the reason.